Pfizer Proceeds with Biotech Manufacturing Expansion in Sweden

Stockholm, Sweden (Dec. 15)-As part of a plan to expand its biotechnology production capacity, Pfizer, Inc. (New York, NY, www.pfizer.com) commissioned the construction company Skanska AB (www.skanska.com) to build a plant in Strångnås, Sweden for manufacturing Pfizer’s human growth hormone product “Genotropin” (somatropin  [rDNA origin] for injection). 

The plant is part of a SEK 1.5 billion ($219 million) investment by Pfizer in the Swedish facility. In addition to building the plant, Skanska also will be responsible for installing process equipment. Skanska's contracts amount to roughly SEK 600 million ($87 million).